Hydromer Announces Strategic Investment by JMEDTECH and Board Restructuring

Hydromer, Inc. has announced a strategic investment from JMEDTECH alongside significant changes to its board leadership structure. The OTC-listed company, which has specialized in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices for over 44 years, described the partnership as transformative for its global positioning.

The collaboration establishes what both companies characterize as a future-oriented global medical device coating platform that integrates UV-curable and thermal-cure coating systems. This comprehensive solution spans research and development, validation processes, and mass production capabilities, supported by advanced coating equipment and regionalized coating services. The partnership creates a mirror-delivery network covering major medical device markets across Asia and the Americas, significantly enhancing supply chain resilience and customer responsiveness.

Michael Torti will continue serving as CEO and director, working alongside newly appointed Chairman Jacqueline Zhang and the restructured board. The company expressed gratitude to departing directors Braeden Lichti and George Kovalyov for their leadership contributions. The board restructuring aims to provide strong leadership, deep industry expertise, and strategic vision as Hydromer enters what company officials describe as its next phase of growth and innovation.

CEO Michael Torti emphasized the significance of the partnership, stating that combining forces with JMEDTECH will bring perhaps the broadest range of coating capabilities to the global medical device marketplace, including automatic large-scale coating systems. He characterized the development as guaranteeing Hydromer's future as a dominant player in its served markets while creating value for shareholders, employees, and customers.

The strategic move amplifies Hydromer's technological and brand influence while marking a critical milestone in JMEDTECH's global expansion strategy. By uniting capabilities across different geographic regions, the partnership addresses growing industry demands for more resilient supply chains and comprehensive coating solutions that can support medical device manufacturers through the entire product development and production lifecycle.

This development comes at a time when the medical device industry faces increasing pressure to enhance product performance, improve patient outcomes, and navigate complex global supply chain challenges. The integrated platform approach represents a significant evolution in how coating technologies are delivered to medical device manufacturers worldwide, potentially setting new standards for industry collaboration and technological integration.